Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Similarly, Sapale said the launch of Mounjaro, which uses the molecule tirzepatide, is expected to give a push to the anti-obesity market. In March 2025, the segment’s moving annual turnover — which ...

Plus, “B&B” streaming in up 8% year-over-year on Paramount+. According to CBS’s press release, the daytime show “follows the entangled lives, passionate loves and high-stakes dramas of the ...

According to a lawsuit filed by Eli Lilly on Monday, April 7, Premier Weight Loss, a spa based in Lilly's own backyard in Indianapolis, buys autoinjector pens filled with tirzepatide, cracks them ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. HealthDay News — For patients with inadequately controlled type 2 diabetes ...

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

At week 40, the change from baseline in HbA1c was −1.44 and −0.67 percent with tirzepatide and dulaglutide escalation to 4.5 mg or maximum tolerated dose, respectively. HealthDay News — For patients ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel increases in serious and potentially fatal comorbidities, particularly type 2 ...

GOT7 singer JAY B has announced the US leg of his 2025 ‘Tape: Re Load’ US tour, featuring concerts in Houston, San Francisco and more. READ MORE: Yeji on going solo: “All the experiences of ...

Undaunted, on Tuesday, Hims & Hers announced it is to offer branded versions of tirzepatide-- the molecule in the other FDA-approved obesity jab, Eli Lilly's Zepbound. It's also gearing up to sell ...

to help me after my 2nd pregnancy.” Mounjaro is the brand name for Tirzepatide, a drug used to treat Type 2 diabetes. In 2023, the United States Food and Drug Administration (FDA) approved it ...

Palatin has announced positive results from its BMT-801 Phase II clinical trial of co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory ...